Literature DB >> 17977723

Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Guangrong Zheng1, Sangeetha P Sumithran, Agripina G Deaciuc, Linda P Dwoskin, Peter A Crooks.   

Abstract

A series of tris-azaaromatic quaternary ammonium salts has been synthesized and evaluated for their ability to inhibit neuronal nicotinic acetylcholine receptors (nAChRs) mediating nicotine-evoked [(3)H]dopamine release from superfused rat striatal slices and for inhibition of [(3)H]nicotine and [(3)H]methyllycaconitine binding to whole rat brain membranes. The 3-picolinium compound 1,3,5-tri-{5-[1-(3-picolinium)]-pent-1-ynyl}benzene tribromide (tPy3PiB), 3b, exhibited high potency and selectivity for nAChR subtypes mediating nicotine-evoked [(3)H]dopamine release with an IC(50) of 0.2 nM and I(max) of 67%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977723      PMCID: PMC3954472          DOI: 10.1016/j.bmcl.2007.10.062

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  30 in total

1.  alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release.

Authors:  S Kaiser; S Wonnacott
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

Review 2.  Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery.

Authors:  L P Dwoskin; P A Crooks
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

3.  Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Peter A Crooks; Joshua T Ayers; Rui Xu; Sangeetha P Sumithran; Vladimir P Grinevich; Lincoln H Wilkins; A Gabriela Deaciuc; David D Allen; Linda P Dwoskin
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

4.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

5.  bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.

Authors:  Joshua T Ayers; Linda P Dwoskin; A Gabriela Deaciuc; Vladimir P Grinevich; Jun Zhu; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2002-11-04       Impact factor: 2.823

6.  Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions.

Authors:  Sharon R Grady; Karen L Murphy; Jian Cao; Michael J Marks; J Michael McIntosh; Allan C Collins
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

7.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.

Authors:  Lincoln H Wilkins; Aaron Haubner; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.

Authors:  Linda P Dwoskin; Sangeetha P Sumithran; Jun Zhu; A Gabriela Deaciuc; Joshua T Ayers; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

9.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.

Authors:  Lincoln H Wilkins; Vladimir P Grinevich; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

10.  Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study.

Authors:  S Rahman; J Zhang; W A Corrigall
Journal:  Neurosci Lett       Date:  2003-09-11       Impact factor: 3.046

View more
  12 in total

1.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

2.  Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.

Authors:  Roger L Papke; Linda P Dwoskin; Peter A Crooks; Guangrong Zheng; Zhenfa Zhang; J Michael McIntosh; Clare Stokes
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

3.  The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic.

Authors:  Joseph R Holtman; Linda P Dwoskin; Cheryl Dowell; Elzbieta P Wala; Zhenfa Zhang; Peter A Crooks; J Michael McIntosh
Journal:  Eur J Pharmacol       Date:  2011-09-17       Impact factor: 4.432

Review 4.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

5.  Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-11-24       Impact factor: 2.823

6.  Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-09-26       Impact factor: 2.823

7.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

8.  bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter.

Authors:  Zhenfa Zhang; Paul R Lockman; Rajendar K Mittapalli; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-08-30       Impact factor: 2.823

9.  Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.

Authors:  Zaineb A Fadhel Albayati; Linda P Dwoskin; Peter A Crooks
Journal:  Drug Metab Dispos       Date:  2008-07-10       Impact factor: 3.922

10.  Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Marharyta Pivavarchyk; Karunai Leela Subramanian; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-01-04       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.